A collection of information regarding Aluminum
Aluminum is poorly absorbed following either oral or inhalation exposure and is essentially not absorbed dermally. Approximately 1.5–2% of inhaled and 0.01–5% of ingested aluminum is absorbed.
Aluminum limits in drinking water
Secondary Maximum Contaminant Level
US EPA SMCL* = 0.05 to 0.2 mg/L
WHO† Guideline = 0.1 to 0.2 mg/L
Health Canada OG** = 0.1 to 0.2 mg/L
“Oral exposure to aluminum is usually not harmful. Some studies show that people exposed to high levels of aluminum may develop Alzheimer’s disease, but other studies have not found this to be true. We do not know for certain that aluminum causes Alzheimer’s disease.”
“Some people who have kidney disease store a lot of aluminum in their bodies. The kidney disease causes less aluminum to be removed from the body in the urine. Sometimes, these people developed bone or brain diseases that doctors think were caused by the excess aluminum.”
• Vaccines may contain small amounts of aluminum compounds, no greater than 0.85 mg/dose.
***(Note that safe drinking limits are 0.05-0.2mg/L and that aluminum is not easily absorbed orally. Yet vaccines contain up to 0.85mg/dose in each vaccine. This is being injected directly into the body bypassing our bodies filtration systems)***
The healthy human body has effective barriers (skin, lungs, gastrointestinal tract) to reduce the systemic absorption of aluminum ingested from water, foods, drugs, and air. The small amount of aluminum (<1%) that is systemically absorbed is excreted principally in the urine and, to a lesser extent, in the feces. No reports of dietary aluminum toxicity to healthy individuals exist in the literature.
Aluminum can be neurotoxic, when injected directly into the brains of animals and when accidentally introduced into human brains (by dialysis or shrapnel).
Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 [micro]g/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
None of the individual vaccines violates the guidance of a maximum of 850 μg of aluminum for an adult (Table 1).
However, because of multiple vaccines typically given together at 2, 4, and 6 months, the CDC schedule violates this limit even assuming an adult weight (; 29,773,196).
Adjusting the safe dose limit based on a child’s weight at these ages therefore results in doses that far exceed the estimated safe limit of acute toxicity (Lyons-Weiler and Ricketson, 29,773,196).
The CDC schedule crosses the recommended limit of aluminum for an adult by recommending multiple vaccinations containing aluminum being delivered together.
Note that on all days of injection the safe limit for a child is exceeded for all three schedules; this points to acute toxicity Fig. 2.
All of these schedules greatly exceed the weight-adjusted limit for aluminum from Lyons-Weiler and Ricketson (29773196). The CDC schedule has the largest violation at 15.9 times the recommended safe level. This occurs at 2 months, when four recommended vaccinations containing aluminum are simultaneously administered.
In addition, modeling the time to clear aluminum from the body using Priest’s equation estimates that for this schedule a child will be over the safe level of aluminum in the body for 149 days from birth to 7 months, constituting about 70 % of days in this period (Fig. 3). This points to chronic toxicity. Over the first two years of life, days over the estimated limit are estimated as 176 days or 24 % of the days in this period.
Occupational studies in workers exposed to aluminum dust in the form of McIntyre powder, aluminum dust and fumes in potrooms, and aluminum fumes during welding provide suggestive evidence that there may be a relationship between chronic aluminum exposure and subclinical neurological effects such as impairment on neurobehavioral tests for psychomotor and cognitive performance and an increased incidence of subjective neurological symptoms.
Neurodegenerative changes in the brain, manifested as intraneuronal hyperphosphorylated neuro filamentous aggregates, is a characteristic response to aluminum in certain species and nonnatural exposure situations generally involving direct application to brain tissue, particularly intracerebral and intracisternal administration and in vitro incubation in rabbits, cats, ferrets, and nonhuman primates.
Significant alterations in motor function, sensory function, and cognitive function have been detected following exposure to adult or weanling rats and mice or following gestation and/or lactation exposure of rats and mice to aluminum lactate, aluminum nitrate, and aluminum chloride.
•There is a parallel rise in AlAd in vaccines for infants and ASD.
•Injected Al induces behavioral changes in mice.
•Brains in ASD patients contain more Al than control.
•Numerous mechanisms exist that can explain Al neurotoxic effects.
•The consilience of evidence supports AlAd as an etiologic factor in ASD.
When aluminum was first approved for use in vaccines, it was approved based on its efficacy. It was never actually tested for safety. It was simply assumed to be safe.
Aluminum has been shown to cause mitochondrial dysfunction and depletion of adenine-triphosphate, which sets the stage for virtually any chronic disease. Aluminum salts can increase levels of glial activation, inflammatory cytokines and amyloid precursor protein within the brain.
Recent research found the Centers for Disease Control and Prevention’s (CDC) vaccine schedule — when adjusted for body weight — exposes children to a level of aluminum that is 15.9 times higher than the recommended “safe” level.